

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

### In the Application of

Jonathan STAMLER et al.

Serial No. 10/646,713

: Group Art Unit: 1615

Filed: August 25, 2003

: Examiner:

For: USE OF NITRIC OXIDE ADDUCTS

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom. Copies of any cited U.S. Patents and U.S. Patent Publications are not being submitted in accordance with 37 CFR 1.98(a)(2)(i).

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the

right to prove that the date of publication is in fact different.

Applicants' representative certifies that the enclosed documents were cited in a communication from the European Patent Office in a counterpart foreign application not more than three months before the filing date of this Information Disclosure Statement.

No fee is believed to be required, however, the Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

WILMER CUTLER PICKERING HALE AND DORR LLP

  
Edward D. Grieff

Registration No. 38,898

1455 Pennsylvania Avenue, NW  
Washington, DC 20004

TEL 202.942.8400 EDG/mgm

FAX 202.942.8484

Date: \_\_\_\_\_

6 December 2004

**INFORMATION DISCLOSURE  
CITATION IN AN  
APPLICATION**



(PTO-1449)

ATTY. DOCKET NO.  
102258.121US3

SERIAL NO.  
10/646,713

APPLICANT  
Jonathan STAMLER et al.

FILING DATE  
August 25, 2003

GROUP  
1615

**U.S. PATENT DOCUMENTS**

EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	4,954,526	09/04/90	Keefer			02/28/89
	5,002,964	03/26/91	Loscalzo			06/15/98
	5,004,461	04/02/91	Wilson			03/23/89

**FOREIGN PATENT DOCUMENTS**


EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No

**OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)**


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>   (PTO-1449)				ATTY. DOCKET NO. 102258.121US3		SERIAL NO. 10/646,713	
				APPLICANT Jonathan STAMLER et al.			
				FILING DATE August 25, 2003		GROUP 1615	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	JP 1-500592		Japan				X
	WO 92/18002	10/29/92	WIPO			X	
	WO 93/09806	05/27/93	WIPO			X	
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
	Yamakado, Toshiyuki. 1982. "Stimulation of Human Platelet Guanylate Cyclase by Nitroso Compounds." <i>Thrombosis Research</i> , Vol. 26. pp. 135-140.						
	Hollman, Jay M.D. et al. October 1983. "Acute occlusion after percutaneous transluminal coronary angioplasty - a new approach." <i>Circulation</i> , Vol. 68, No. 4. pp. 725-732.						
	Fuster, Valentin et al. March/April 1987. "Platelet-Inhibitor Drugs' Role in Coronary Artery Disease." <i>Progress in Cardiovascular Diseases</i> , Vol. 29, No. 5. pp. 325-346.						
	Kariya, Ken-ichi. 1989. "Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells." <i>Atherosclerosis</i> , Vol. 80. pp. 143-147.						
	Henry, Peter J. et al. 1989. "S-nitrosothiols as vasodilators: implications regarding tolerance to nitric oxide-containing vasodilators." <i>Br. J. Pharmacol.</i> Vol. 98. pp. 757-766.						
	Feelisch, Martin and Malte Kelm. October 15, 1991. "Biotransformation of Organic Nitrates to Nitric Oxide Vascular Smooth Muscle and Endothelial Cells." <i>Biochemical and Biophysical Research Communication</i> , Vol. 180, No. 1. pp. 286-293.						
	Bassenge, E. 1991. "Inhibition of platelet activation by EDRF/NO and by NO-releasing dilator compounds." <i>Zeitschrift fur Kardiologie</i> . Vol. 80. pp. 17-21.						
	Bassenge, E. 1991. "Endothelabhängige Mechanismen der Gefäßregulation." <i>Verhandlungen der Deutschen Gesellschaft Fuer Innere Medizin</i> , Vol. 97. pp. 567-573.						
	Stamler, Jonathan S. and Joseph Loscalzo. 1992. "Endothelium-Derived Relaxing Factor Modulates the Atherothrombogenic Effects of Homocysteine." <i>Journal of Cardiovascular Pharmacology</i> , Vol. 20. pp. S202 - S204.						
	Stamler, Jonathan S. et al. January 1993. "Adverse Vascular Effects of Homocysteine Are Modulated by Endothelium-derived Relaxing Factor and Related Oxides of Nitrogen." <i>The Journal of Clinical Investigation, Inc.</i> , Vol. 91. pp. 308-318.						
	Simon, Daniel I. et al. June 1993. "Antiplatelet Properties of Protein S-Nitrosothiols Derived from Nitric Oxide and Endothelium-Derived Relaxing Factor." <i>Arteriosclerosis and Thrombosis</i> , Vol. 13, No. 6. pp. 791 - 799.						
	September 6, 2004. European Search Report from European Patent Application No. EP 03 02 6675.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.